Ascendis Pharma A/S Cash And Cash Equivalents
Ascendis Pharma A/S (ASND) had Cash And Cash Equivalents of EUR 616.04 million as of 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Notes
ifrs-full:CashAndCashEquivalents · last filed 2026-02-11
- 2025-12-31: Cash And Cash Equivalents 616.04M EUR.
- 2025-09-30: Cash And Cash Equivalents 539.09M EUR.
- 2025-06-30: Cash And Cash Equivalents 494.05M EUR.
- 2025-03-31: Cash And Cash Equivalents 517.92M EUR.
| Period end | Cash And Cash Equivalents |
|---|---|
| 2025-12-31 | 616.04M EUR 20-F · filed 2026-02-11 |
| 2025-09-30 | 539.09M EUR 6-K · filed 2025-11-12 |
| 2025-06-30 | 494.05M EUR 6-K · filed 2025-08-07 |
| 2025-03-31 | 517.92M EUR 6-K · filed 2025-05-01 |
| 2024-12-31 | 559.54M EUR 20-F · filed 2026-02-11 |
| 2024-09-30 | 625.51M EUR 6-K · filed 2025-11-12 |
| 2024-06-30 | 258.70M EUR 6-K · filed 2025-08-07 |
| 2024-03-31 | 320.24M EUR 6-K · filed 2025-05-01 |
| 2023-12-31 | 392.16M EUR 20-F · filed 2026-02-11 |
| 2023-09-30 | 441.27M EUR 6-K · filed 2024-11-14 |
| 2023-06-30 | 394.22M EUR 6-K · filed 2024-09-03 |
| 2023-03-31 | 501.28M EUR 6-K · filed 2024-05-02 |
| 2023-01-01 | 444.77M EUR 20-F · filed 2025-02-12 |
| 2022-12-31 | 444.77M EUR 20-F · filed 2026-02-11 |
| 2022-09-30 | 608.33M EUR 6-K · filed 2023-11-07 |
| 2022-06-30 | 672.39M EUR 6-K · filed 2023-09-05 |
| 2022-03-31 | 755.64M EUR 6-K · filed 2023-04-27 |
| 2021-12-31 | 446.27M EUR 20-F · filed 2025-02-12 |
| 2021-09-30 | 692.94M EUR 6-K · filed 2022-11-02 |
| 2021-06-30 | 384.54M EUR 6-K · filed 2022-08-10 |
| 2021-03-31 | 495.05M EUR 6-K · filed 2022-05-11 |
| 2020-12-31 | 584.52M EUR 20-F · filed 2024-02-07 |
| 2020-09-30 | 763.45M EUR 6-K · filed 2021-11-10 |
| 2020-06-30 | 240.60M EUR 6-K · filed 2021-08-27 |
| 2020-03-31 | 534.38M EUR 6-K · filed 2021-05-27 |
| 2019-12-31 | 598.11M EUR 20-F · filed 2023-02-16 |
| 2019-09-30 | 658.66M EUR 6-K · filed 2020-11-12 |
| 2019-06-30 | 690.36M EUR 6-K · filed 2020-08-27 |
| 2019-03-31 | 696.66M EUR 6-K · filed 2020-05-19 |
| 2018-12-31 | 277.86M EUR 20-F · filed 2022-03-02 |
| 2018-09-30 | 310.33M EUR 6-K · filed 2019-11-18 |
| 2018-06-30 | 352.60M EUR 6-K · filed 2019-08-28 |
| 2018-03-31 | 348.41M EUR 6-K · filed 2019-05-30 |
| 2017-12-31 | 195.35M EUR 20-F · filed 2021-03-10 |
| 2017-09-30 | 206.29M EUR 6-K · filed 2018-11-28 |
| 2017-06-30 | 127.32M EUR 6-K · filed 2018-08-29 |
| 2017-03-31 | 157.65M EUR 6-K · filed 2018-05-30 |
| 2016-12-31 | 180.33M EUR 20-F · filed 2020-04-03 |
| 2015-12-31 | 119.65M EUR 20-F · filed 2019-04-03 |
| 2014-12-31 | 50.17M EUR 20-F · filed 2018-03-28 |